|
|
 |
|
Viewing report
|
|
|
|
Urinary Incontinence: Major Milestones
Datamonitor, March 2005
Urinary incontinence has three main subtypes including stress, urge and mixed, and is estimated to affect 100 million women in the seven major markets. Drug therapy for urinary incontinence has focused on overactive bladder, worth over $1.3 billion in 2003. Lilly/BI's Yentreve, launched in 2004, is the first drug treatment for stress incontinence, the most prevalent subtype of the condition.
Report Scope
- In-depth primary research interviews with key opinion leaders from the US and Europe to add insight on market developments and unmet needs
- Analysis of recent market events including new drug launches and impact on the market
- Secondary resources include IMS MIDAS sales and promotional data across the seven major markets, IDdb, IMS R&D Focus, Medline
Report Highlights
Despite the high prevalence of urinary incontinence among women, few are diagnosed and treated due to a number of barriers preventing help-seeking behavior. There is a need to greater disease education among patients to lessen embarrassment about the condition and raise awareness of effective treatments.
The UI market was worth $1.3 billion in 2003 with sales dominated by leading overactive bladder drugs including Detrol (Pfizer) and oxybutynin in its various forms. New drug launches in OAB Vesicare (Yamanouchi) and Enablex (Novartis) could usurp Pfizer's dominance, while Yentreve will open up a new and underserved segment and driving growth.
Opinion leaders have identified a number of unmet needs in the urinary incontinence market, particularly the need for greater support for health professionals in terms of differentiating, diagnosing and treating UI subtypes in the long term and the need for greater disease awareness both among patients and physicians.
Why you should buy this report
1. Understand barriers to treatment in the female UI population including obstacles in help-seeking behavior and difficulties in the diagnostic pathway
2. Identify physicians key concerns in urinary incontinence including unmet needs and desirable attributes of novel drugs for Overactive Bladder
3. Evaluate new drugs entering the market including key efficacy and safety trial data and their potential impact on the market
This product has been designed for delivery in a slide pack format (ppt).
Customers who bought this item also bought
Management of Urinary Incontinence and Overactive Bladder - A Global Overview
Stress Urinary Incontinence - Opinion Divided on Drug Therapy
Pipeline and Commercial Insight: Urinary Incontinence - Lifecycle management strategies retain mid-term market growth
European Urinary Incontinence Therapeutics Markets
Urinary Incontinence Devices Market: An Analysis
Trends and Developments in the European Urinary Incontinence
Urinary Incontinence and Overactive Bladder - The Perspective of the Continence Nurse in the US
Urinary Incontinence: Market Update - Growing Market Brings Opportunities for New Drugs
Strategic Perspectives 2002: CNS Disorders in Women - Urinary Incontinence
Mixed Urinary Incontinence - An Opportunity for Novel Drug Therapies
Urge Urinary Incontinence - Poor Differentiation Limiting New Product Uptake
US market size for urinary incontinence ( UI ) drugs by sales in dollars, by number of prescriptions, and by number of overactive bladder sufferers and urge UI sufferers for 1999 and forecast for 2000 to 2004; also, breakout of sales, percent market
|
|
|
|
